depression medication

Tiny biotech Clinical Data has developed a potential blockbuster called Vilazodone. If OK'd, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas may be looking to buy the startup.

According to a report in today's PLos Medicine, a group of scientists who carried out a meta-analysis of the efficacy of Prozac and other selective serotonin re-update inhibitor (SSRI) medications used to treat depression found that there was no clinically significant benefit to any except the most...